205 East 42nd Street, 16th Floor
76 articles with Neurotrope
Neurotrope Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Charles Ryan, J.D., Ph.D., Neurotrope's Chief Executive Officer, will be participating in an educational panel entitled, "Attacking Biological Mechanisms of Aging to Extend Healthspan" at the BIO CEO & Investor Conference
Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute
Collaboration to Support Clinical Study of Bryostatin-1 in Leukemia and B-cell Lymphoma
Neurotrope (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Daniel Alkon, M.D., Neurotrope's President and Chief Scientific Officer, will be participating in a panel discussion entitled "Progress in Alzheimer's" at the Sachs Associates 2nd Annual Neuroscience Innovation Forum in San Francisco on Sunday, January 6th, 2019
Neurotrope (Nasdaq:NTRP) today announced the pricing of a registered direct offering of 5,012,677 shares of common stock and warrants to purchase up to an aggregate of 5,012,677 shares of common stock to institutional and other accredited investors.
Neurotrope (NASDAQ:NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced the appointment of two new members to its Board of Directors - Ivan Gergel, M.D., Managing Partner and Chief Medical Officer of New Rhein Healthcare Investors LLC, and Jonathan Schechter, Director of Investment Banking at Chardan Capital Markets.
Neurotrope Announces Publication of Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease in the Journal of Alzheimer's Disease
Publication Highlights Bryostatin's Neurorestorative Potential in the Most Challenging-to-treat and Underserved AD Patient Population
Neurotrope Presents Updated Phase 2 Data of Bryostatin-1 in Moderate to Severe Alzheimer's Disease at the 11th Edition of CTAD
The data were presented in a poster, entitled "Evidence of Sustained Low Dose Bryostatin Efficacy for Treatment of Alzheimer's Disease: Consistency of Multiple Evaluation Analyses" at the 11th Edition of Clinical Trials on Alzheimer's Disease ("CTAD") being held in Barcelona, Spain from October 24th - 27th, 2018.
Neurotrope, Inc. today announced that Dr. Charles Ryan, Neurotrope's Chief Executive Officer, will present a company overview at the Ladenburg Thalmann 2018 Healthcare Conference in New York on Tuesday, October 2nd, 2018 at 9:30 a.m. Eastern Time.
Neurotrope Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City September 4-6, 2018
Neurotrope has also been selected to present at the 25th Annual NewsMakers in the Biotech Industry on September 7th, 2018
As of June 30, 2018, the Company had approximately $11.8 million of cash and cash equivalents
At AAIC 2018, Neurotrope Presents Additional Clinical Results Showing Cognitive Improvement in Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients
Patients treated with 20 µg Bryostatin-1 showed evidence of sustained improvement in cognition compared with placebo in patients not on concomitant memantine treatment
Neurotrope, Inc. is announcing that it has established its Scientific Advisory Board (SAB) comprised of experts in the fields of AD and other Neurological diseases.
Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting
The Alzheimer's Association International Conference 2018 (AAIC) is being held in Chicago, from July 22-26, 2018.
Neurotrope, In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 Trial in Advanced Alzheimer's Patients
Neurotrope, Inc. is announcing that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, has completed the study design for its confirmatory Phase 2 clinical trial in moderate to severe Alzheimer's disease.
Yet another Alzheimer’s drug has failed in late-stage clinical trials. vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in its Phase III STEADFAST clinical trial. It was being evaluated in patients with mild Alzheimer’s disease.
Neurotrope today announced that Daniel Alkon, MD, President and Chief Scientific Officer of Neurotrope, will present at the BIO CEO & Investor Conference to be held in New York City from February 12th-13th.
Neurotrope's corporate presentation will take place on Tuesday, January 30th at 8:30 AM EST in Studio 2.
Neurotrope's Bryostatin Improves Cognition in Patients With Advanced Alzheimer's Disease Based on Further Analysis of Phase II Clinical Trial Data
The findings suggest this investigational drug could potentially help treat the progression of AD, rather than only its symptoms.
Neurotrope to Present Additional Findings From Bryostatin Phase II Trial in Advanced Alzheimer's Disease
Daniel Alkon, MD, President and CSO of Neurotrope, will also be presenting at the 10th Annual Biotech Showcase Conference taking place in San Francisco from January 8 -10, 2018.
12/18/2017Dr. Ryan becomes a Director of the Company effective immediately and will assume his responsibilities as CEO effective February 15, 2018.